The post Forget SPCX: As Continuous Volatility Shakes Tech, This $34 Exchange-Traded Fund Is a No-Brainer Buy Without The Post-IPO Risk appeared first on 24/7 Wall St..
SpaceX (NASDAQ:SPCX) is the only ticker financial media wants to discuss this week after its blockbuster public debut at an implied trillion-dollar valuation. But here’s what you should actually be watching.
The ARK Space Exploration & Innovation ETF (NYSEARCA:ARKX) trading near $34 a share offers diversified exposure to the space economy. Rocket launches and massive satellite arrays require billions in unceasing capital expenditure, and a single-name bet on a freshly listed giant is the worst way to underwrite that bill.
SPCX went public on June 12, 2026 and the wheels have started to wobble inside a week. Shares opened to euphoria, briefly cleared $220 in overnight trading, and settled at $185 by June 18. Reddit sentiment collapsed from a bullish score of 76 on June 13 to a very bearish 12 by June 18, with the dominant retail post warning “SPCX, Beware, institutional money is NOT buying this trash on the open market” drawing over 1,000 upvotes in a single day. A separate top thread, “The math isn’t mathing on the SpaceX IPO,” drew over 1,000 comments.
That is textbook hype-cycle anatomy. Insider lockup expirations are still ahead. There is no public earnings history to underwrite. The implied market capitalization already prices in roughly a decade of flawless execution on Starlink, Starship, and Mars before SPCX has filed a single quarterly report as a public entity.
1. You own the entire aerospace value chain. ARKX spreads capital intensity across launchers, satellite operators, propulsion suppliers, and ground-segment vendors. One Starship anomaly or one FAA delay does not blow up the position the way it would with a single ticker carrying a trillion-dollar valuation.
2. You capture public players printing real numbers. Consider Rocket Lab (NASDAQ:RKLB), the pure-play space stock that institutional aerospace funds anchor around. Rocket Lab posted Q1 2026 revenue of $200.35 million, up 63.5% year over year, with a $2.20 billion backlog and Q2 guidance of $225 million to $240 million. It joins the Nasdaq-100 Index on June 22, 2026 and was selected for the Department of War’s Space Based Interceptor program under Golden Dome for America. Audited, contracted revenue with a Pentagon stamp on it.
3. No lockup cliff, no dilution roulette. Fresh listings carry insider lockup expirations, secondary offerings, and price discovery that has wrecked plenty of trillion-dollar narratives in the first twelve months. A diversified basket sidesteps that mechanical headwind. You also get exposure to the whole sector for a fraction of one SPCX share, which matters when SPCX trades at $185 after a 14.94% one-week move.
The space sector is volatile. Rocket Lab is down 15.76% over the past month, continues to post GAAP losses (a $45.02 million net loss in Q1), and is funding Neutron through ATM equity dilution. A diversified ETF softens those single-name shocks. It does not eliminate them.
The math is uncomplicated. SPCX wants you to underwrite a trillion-dollar valuation with zero public financials, days into a listing whose retail sentiment has already cratered. ARKX hands you the same launch-and-satellite tailwind through a basket stacked with operators like Rocket Lab, a company compounding revenue at 63.5% year over year and backlog at 20.2% sequentially.
The headline trade is crowded. The basket offers diversified exposure.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Rocket Lab didn’t make the cut. Grab the names FREE today.
The post Forget SPCX: As Continuous Volatility Shakes Tech, This $34 Exchange-Traded Fund Is a No-Brainer Buy Without The Post-IPO Risk appeared first on 24/7 Wall St..


